Skip to main content
Meet Omvoh
Woman outside looking into distance

Lilly Support Services for Omvoh offers the support you need, when you need it

Enrolling in Lilly Support Services, a customer support program, can be a way to help you with your Omvoh treatment journey. By enrolling in this program, you will receive services and resources to help you understand what to expect when starting on Omvoh.

The program can help you get started by connecting you with:

  • Savings* and insurance assistance that may help you pay for the medication

  • An infusion center to help you feel ready beginning treatment

  • Injection training to help you feel more prepared using your Omvoh injection devices

  • Sharps disposal containers to provide a convenient and safe way for you to dispose of your used Omvoh injection devices

  • One-on-one support with a Companion in Care™† representative who can help answer questions, and offer personalized support along your treatment journey

For additional support on your Omvoh journey or to ask questions, call 1-800-Lilly-Rx (1-800-545-5979).

For eligible and commercially insured patients

Pay as little as $5 or $0 per treatment with the Omvoh Savings Program*

coupon*Governmental beneficiaries excluded, terms and conditions apply.

Treatment is defined as one infusion or one 28-day supply of injections.

Your Companion in Care provided by Lilly Support Services for Omvoh is not a medical professional. Your doctor is your source for medical advice.

By enrolling in the Omvoh Savings Card Program (“Program”) and using the Omvoh Savings Card (“Card”), you attest that you meet the eligibility criteria, agree to, and will comply with the terms and conditions described below:

Eligibility:

(1) You have been prescribed Omvoh® (mirikizumab-mrkz) for an approved use consistent with FDA approved product labeling;

(2) You are enrolled in a commercial drug insurance plan;

(3) You are not enrolled in any state, federal, or government funded healthcare program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state prescription drug assistance program;

(4) You are a resident of the United States or Puerto Rico; and

(5) You are 18 years of age or older.

Program savings for Omvoh infusion

For patients with commercial drug insurance with coverage for Omvoh: You must (a) have coverage for Omvoh through your commercial drug insurance but your insurance does not cover the full cost (i.e., you have a co-pay or coinsurance obligation) and (b) have a prescription for an approved use consistent with FDA-approved product labeling to pay as little as $5 for each infusion. The Program will cover your co-pay or coinsurance for Omvoh, less $5, up to the maximum monthly, annual, and lifetime limits outlined below. After the monthly and/or annual maximum savings are reached, you will be responsible for paying any remaining monthly/annual out-of-pocket costs. Card may be used for a maximum of up to 3 infusions over the lifetime of the Program. Program may provide support for infusions with a date of service that falls within 120 days prior to the date the enrollment form is received by the Program.

To receive Program savings, your healthcare provider must submit a claim for coverage to your medical insurance provider. If your medical insurance provider does not cover the full cost of the claim, your healthcare provider must then submit an Explanation of Benefits (EOB) form and a CMS 1450 or 1500 form to Medical Claims Support within 180 days of the infusion date of Omvoh. The submitted form must include the name of the insurer and plan and demonstrate that Omvoh was the medication administered. You understand and agree that Lilly will make a payment of your Program savings on your behalf to your healthcare provider. Participation in the Program requires a valid patient HIPAA authorization upon enrollment into the Program. Subject to Lilly USA, LLC’s (“Lilly”) right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason. Savings may continue until 06/30/2028 or for up to 30 months whichever comes first, provided you continue to meet the Program’s terms and conditions, and you first utilize the Program savings no later than 12/31/2025.

For patients with commercial drug insurance without coverage for Omvoh: You must (a) have commercial drug insurance without coverage for Omvoh, (b) have a prescription for an approved use consistent with FDA-approved product labeling, and (c) be enrolled in the Program on or before the date of the infusion to pay as little as $0 for each infusion. Card may be used for a maximum of up to 3 infusions over the lifetime of the Program. Program savings are subject to maximum monthly, annual, and lifetime limits, outlined below. After the monthly and/or annual maximum savings are reached, you will be responsible for paying any remaining monthly/annual out-of-pocket costs. To receive Program savings, your healthcare provider must submit a prior authorization (PA) request for Omvoh to your insurance provider before initiating treatment with Omvoh and provide the results of the PA demonstrating your insurance provider has denied coverage for non-administrative reasons to Lilly Support Services for Omvoh. Participation in the Program requires a valid patient HIPAA authorization to remain in the Program. Subject to Lilly USA, LLC’s (“Lilly”) right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason. Savings may continue until 06/30/2028 or for up to 30 months whichever comes first, provided you continue to meet the Program’s terms and conditions, and you first utilize the Program savings no later than 12/31/2025.

Program savings for Omvoh injections

For patients with commercial drug insurance with coverage for Omvoh: You must have commercial drug insurance that covers Omvoh and a prescription consistent with FDA-approved product labeling to pay as little as $5 per month for Omvoh injections. Month is defined as 28-days and up to 1 fill. Program savings are subject to maximum monthly,annual, and lifetime limits,outlined below. Card may be used for a maximum of up to 14 prescription fills of the injection per calendar year. Participation in the Program requires a valid patient HIPAA authorization upon enrollment in the Program. Subject to Lilly USA, LLC’s (“Lilly”) right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason. Savings may continue until 06/30/2028 or for up to 30 months whichever comes first, provided you continue to meet the Program’s terms and conditions, and you first utilize the Program savings no later than 12/31/2025.

For patients with commercial drug insurance without coverage for Omvoh: You must have commercial drug insurance without coverage for Omvoh and a prescription consistent with FDA-approved product labeling to pay as little as $0 per month for Omvoh injections. Month is defined as 28 days and up to 1 fill. Program savings are subject to maximum monthly, annual, and lifetime limits, outlined below. Card may be used for a maximum of up to 14 prescription fills of the injection per calendar year. Participation in the Program requires a valid patient HIPAA authorization to remain in the Program. To receive Program savings, your healthcare provider must submit a prior authorization (PA) request for Omvoh to your insurance provider prior to your 1st fill of Omvoh and provide the results of the PA demonstrating your insurance provider has denied coverage for non-administrative reasons to Lilly Support Services for Omvoh. To continue receiving Program savings, your healthcare provider must submit an appeal of the denial of coverage to your insurance provider prior to your 5th fill and provide the results of the appeal demonstrating your provider has denied coverage for non-administrative reasons to Lilly Support ServicesTM for Omvoh. To remain eligible for the Program, a new PA, appeal, or medical exception must be submitted prior to the 13th fill and as required by Lilly at its sole discretion. Subject to Lilly USA, LLC’s (“Lilly”) right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason. Savings may continue until 06/30/2028 or for up to 30 months whichever comes first, provided you continue to meet the Program’s terms and conditions, and you first utilize the Program benefits no later than 12/31/2025.

Monthly, annual, and lifetime maximum savings for the Program
Program savings are limited to a maximum of 30 months.
For patients with commercial drug insurance with coverage for Omvoh: Program savings for claims covered under the medical and/or pharmacy portion of your medical insurance for Omvoh are limited to up to 3 infusions over the lifetime of the Program and up to 14 injection fills per calendar year, subject to a combined (injection and infusion) maximum monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges and a separate maximum annual savings of $9,200 for each calendar year. Monthly and annual maximums are set at Lilly’s absolute discretion and may be changed by Lilly with or without notice.
For patients with commercial drug insurance without coverage for Omvoh: Program savings for claims not covered under the medical and/or pharmacy portion of your medical insurance are limited to up to 3 infusions over the lifetime of the Program and up to 14 injection fills per calendar year, subject to a combined (injection and infusion) maximum monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges and a separate annual maximum savings. Monthly and annual maximums are set at Lilly’s absolute discretion and may be changed by Lilly with or without notice.

Additional Program Terms and Conditions
If you have an insurance plan that is participating in an alternate funding program (“AFP”) that requires you to apply to the Omvoh Savings Card Program or otherwise pursue specialty drug prescription coverage through an alternate funding vendor as a condition of, requirement for, or prerequisite to coverage of Omvoh, you are not eligible for and are prohibited from using the Omvoh Savings Card Program.AFPs include programs where coverage, reimbursement, or patient out of pocket costs for a product in some way vary based on the availability of a manufacturer co-pay program. AFPs may modify, delay, deny, restrict, or withhold insurance benefits or coverage from patients, or exclude Lilly products from coverage contingent upon a member’s use of Omvoh Savings Card Program. You agree to inform Omvoh Savings Card Program if you are or become a member of such an alternate funding program. You are responsible for any applicable taxes, fees, and any amount that exceeds the monthly or annual maximum savings. Monthly and annual maximum savings are set at Lilly’s sole and absolute discretion and may be changed by Lilly with or without notice at any time for any reason. At its sole discretion and with or without notice, Lilly may reduce, eliminate, or otherwise modify the Card savings for any reason, including but not limited to if your commercial drug insurance plan imposes additional requirements which limits or prevents you from receiving coverage for Omvoh, only allows partial coverage for Omvoh, removes coverage for Omvoh and requires you to utilize the Card, does not provide a material level of financial assistance for the cost of Omvoh, or does not apply Card payments to satisfy your co-payment, deductible, or coinsurance for Omvoh.

Program savings are limited to the co-pay or coinsurance costs for Omvoh only, subject to a monthly and annual maximum savings, outlined above. The Program will not cover, and shall not be applied toward, the cost of any dosing procedure, any other healthcare provider service or supply charges or other treatment costs, or any costs associated with a hospital stay. Program will only be accepted at participating pharmacies. Patients with commercial drug insurance without coverage for Omvoh must use Lilly’s designated pharmacy vendor to obtain Program savings. Card savings are not valid for: Massachusetts residents if an AB-rated generic equivalent is available; California residents if an FDA-approved therapeutic equivalent is available. You must meet the Card eligibility criteria, terms and conditions every time you use the Card. If at any time you begin receiving drug coverage under any state, federal, or government funded healthcare program, you understand that you will no longer be eligible for the Omvoh Savings Card and agree to call Lilly Support Servicesfor Omvoh at 1-800-LillyRx (1-800-545-5979) to stop participation. Card activation is required. You may not seek reimbursement from your health insurance, any third party, or any health savings, flexible spending, or other healthcare reimbursement accounts, for any amount of the savings received through the Card. By utilizing the Card, you agree that if you are required to do so under the terms of your insurance coverage for this prescription or are otherwise required to do so by law, you will notify your Insurance Carrier of your redemption of the Card. Card savings cannot be combined or utilized with any other program, discount, discount card, cash discount card, coupon, incentive, or similar offer involving Omvoh. You agree that th is Card savings is intended solely for the benefit of you, the patient, and that the Card benefits are nontransferable. It is prohibited for any person to sell, purchase, or trade; or to offer to sell, purchase, or trade, or to counterfeit the Card. THIS CARD IS NOT INSURANCE. Lilly has the sole right to interpret and apply Card eligibility criteria, and terms and conditions. Card eligibility, and terms and conditions may be terminated, rescinded, revoked, or amended by Lilly at any time without notice and for any reason. Lilly’s sole discretion to terminate, rescind, revoke, or amend Card eligibility and/or Card terms and conditions includes the right to terminate any individual Card if Lilly determines, in its sole discretion, that a patient does not satisfy the Card’s eligibility criteria or is using or has attempted to use the Card inconsistently with these terms and conditions. Eligibility criteria, and terms and conditions for the Omvoh Savings Card Program may change from time to time; the most current version can be found at Savings and Support. You may be required to obtain a new Card, including if any Card terms and conditions have been terminated, rescinded, revoked, or amended by Lilly. Card void where prohibited by law. Subject to Lilly USA, LLC’s (“Lilly”) right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason, savings may continue until 06/30/2028 or for up to 30 months whichever comes first, provided you continue to meet the Program’s terms and conditions and you first utilize the Program benefits no later than 12/31/2025.
TRICARE® is a registered trademark of the Department of Defense (DoD), DHA.

SAFETY SUMMARY

Warnings – Omvoh can cause serious side effects including:

Serious allergic reactions: Omvoh may cause serious allergic reactions that may need to be treated in a hospital and may be life-threatening. Do not use Omvoh if you have had a serious allergic reaction to mirikizumab-mrkz or any of the ingredients in Omvoh. See the Medication Guide that comes with Omvoh for a list of ingredients. Stop using Omvoh and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:

  • fainting, dizziness, feeling lightheaded

  • swelling of your face, eyelids, lips, mouth, tongue, throat, or trouble swallowing

  • trouble breathing, throat tightening, or wheezing

  • chest tightness

  • fast heartbeat or pounding in your chest

  • severe itching, hives, or redness all over your body

  • sweating

Infections: Omvoh may lower the ability of your immune system to fight infections and may increase your risk of infections. If you have an infection, your healthcare provider should not start treatment with Omvoh until your infection is gone. Before starting treatment with Omvoh, your healthcare provider should assess you for tuberculosis (TB). If you are at risk for TB, you may be treated with medicine for TB before you begin treatment with Omvoh. Your healthcare provider should watch you closely for signs and symptoms of TB while you are being treated with Omvoh and after treatment.

Before starting Omvoh, tell your healthcare provider if you think you have an infection or have symptoms of an infection, such as:

  • fever, sweating, or chills

  • muscle aches and pain

  • cough or shortness of breath

  • blood in your mucus (phlegm)

  • flu-like symptoms

  • headache

  • warm, red, or painful skin or sores on your body

  • diarrhea or stomach pain

  • weight loss

  • nausea or vomiting

  • pain during urination

After starting Omvoh, tell your healthcare provider right away if you have any symptoms of an infection.

Liver Problems: Omvoh may cause liver problems. Your healthcare provider should do blood tests to check your liver enzyme and bilirubin levels before treatment, during, and after treatment with Omvoh. Your healthcare provider may hold or stop treatment if needed. Tell your healthcare provider right away if you develop any signs and symptoms of liver problems, including:

  • unexplained rash

  • nausea

  • vomiting

  • stomach-area (abdominal) pain

  • feeling tired

  • loss of appetite

  • yellowing of the skin or the whites of your eyes

  • dark urine

Common side effects

The most common side effects of Omvoh in people treated for ulcerative colitis include:

  • upper respiratory infections

  • injection site reactions

  • joint pain

  • rash

  • headache

  • herpes viral infections

The most common side effects of Omvoh in people treated for Crohn’s disease include:

  • upper respiratory infections

  • injection site reactions

  • headache

  • joint pain

  • elevated liver blood tests

These are not all the possible side effects of Omvoh.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before you use Omvoh, review these questions with your doctor:

  • Are you being treated for an infection?

  • Do you have an infection that does not go away or keeps coming back?

  • Do you have TB or have you been in close contact with someone with TB?

  • Do you have any possible symptoms of an infection such as fever, chills, muscle aches, cough, shortness of breath, runny nose, sore throat, or pain during urination?

Tell your doctor about all your medical conditions, including if:

  • You have a history of serious allergic reaction to Omvoh, any infections or liver problems.

  • You need any vaccines or have had one recently. Medicines that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during or right after treatment with Omvoh. Tell your healthcare provider that you are taking Omvoh before receiving a vaccine.

  • You are pregnant, or plan to become pregnant. It is not known if Omvoh will harm your unborn baby. There will be a pregnancy registry to collect information about women who are exposed to Omvoh during pregnancy. If you become pregnant while taking Omvoh, you are encouraged to report your pregnancy to Eli Lilly and Company at 1-800-545-5979.

  • You are breastfeeding or plan to breastfeed. It is not known if Omvoh passes into your breastmilk.

  • You take prescription or over-the-counter medicines, vitamins, or herbal supplements.

How to take

Follow your healthcare provider’s instructions for using Omvoh. You will receive your first 3 doses of Omvoh through a vein in your arm (intravenous infusion) in a healthcare facility by a healthcare provider every 4 weeks. Each infusion will last about 30 minutes (for ulcerative colitis) or about 90 minutes (for Crohn’s disease). After induction, you will continue to receive Omvoh maintenance doses as self-injections under the skin (subcutaneous injection) every 4 weeks. For these injections, Omvoh is available as prefilled pens or prefilled syringes. For a full dose you will need two injections with either two prefilled pens or two prefilled syringes. Inject 1 Omvoh prefilled pen or prefilled syringe followed right away by the other Omvoh prefilled pen or prefilled syringe. If you give injections at home, you should be trained on the correct way to prepare and inject Omvoh. Do not try to inject Omvoh yourself until you or your caregiver have been shown how to inject. Read the detailed Instructions for Use about how to use and dispose of Omvoh the correct way.

Learn more

Omvoh is a prescription medicine. During induction, Omvoh is available as a single-dose vial for intravenous infusion containing 300 mg/15 mL that is administered in a healthcare facility.

During maintenance, Omvoh is available as:

  • For ulcerative colitis: two 100 mg/mL prefilled pens or prefilled syringes.

  • For Crohn’s disease: one 100 mg/mL prefilled pen or prefilled syringe and one 200 mg/2 mL prefilled pen or prefilled syringe.

For more information, call 1-800-545-5979 or go to omvoh.lilly.com.

This summary provides basic information about Omvoh but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Omvoh and how to take it. Your doctor is the best person to help you decide if Omvoh is right for you.

MR CON BS CD APP

Omvoh® and its delivery device base are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

SAFETY SUMMARY

Warnings – Omvoh can cause serious side effects including:

Serious allergic reactions: Omvoh may cause serious allergic reactions that may need to be treated in a hospital and may be life-threatening. Do not use Omvoh if you have had a serious allergic reaction to mirikizumab-mrkz or any of the ingredients in Omvoh. See the Medication Guide that comes with Omvoh for a list of ingredients. Stop using Omvoh and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:

  • fainting, dizziness, feeling lightheaded

  • swelling of your face, eyelids, lips, mouth, tongue, throat, or trouble swallowing

  • trouble breathing, throat tightening, or wheezing

  • chest tightness

  • fast heartbeat or pounding in your chest

  • severe itching, hives, or redness all over your body

  • sweating

Infections: Omvoh may lower the ability of your immune system to fight infections and may increase your risk of infections. If you have an infection, your healthcare provider should not start treatment with Omvoh until your infection is gone. Before starting treatment with Omvoh, your healthcare provider should assess you for tuberculosis (TB). If you are at risk for TB, you may be treated with medicine for TB before you begin treatment with Omvoh. Your healthcare provider should watch you closely for signs and symptoms of TB while you are being treated with Omvoh and after treatment.

Before starting Omvoh, tell your healthcare provider if you think you have an infection or have symptoms of an infection, such as:

  • fever, sweating, or chills

  • muscle aches and pain

  • cough or shortness of breath

  • blood in your mucus (phlegm)

  • flu-like symptoms

  • headache

  • warm, red, or painful skin or sores on your body

  • diarrhea or stomach pain

  • weight loss

  • nausea or vomiting

  • pain during urination

After starting Omvoh, tell your healthcare provider right away if you have any symptoms of an infection.

Liver Problems: Omvoh may cause liver problems. Your healthcare provider should do blood tests to check your liver enzyme and bilirubin levels before treatment, during, and after treatment with Omvoh. Your healthcare provider may hold or stop treatment if needed. Tell your healthcare provider right away if you develop any signs and symptoms of liver problems, including:

  • unexplained rash

  • nausea

  • vomiting

  • stomach-area (abdominal) pain

  • feeling tired

  • loss of appetite

  • yellowing of the skin or the whites of your eyes

  • dark urine

Common side effects

The most common side effects of Omvoh in people treated for ulcerative colitis include:

  • upper respiratory infections

  • injection site reactions

  • joint pain

  • rash

  • headache

  • herpes viral infections

The most common side effects of Omvoh in people treated for Crohn’s disease include:

  • upper respiratory infections

  • injection site reactions

  • headache

  • joint pain

  • elevated liver blood tests

These are not all the possible side effects of Omvoh.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before you use Omvoh, review these questions with your doctor:

  • Are you being treated for an infection?

  • Do you have an infection that does not go away or keeps coming back?

  • Do you have TB or have you been in close contact with someone with TB?

  • Do you have any possible symptoms of an infection such as fever, chills, muscle aches, cough, shortness of breath, runny nose, sore throat, or pain during urination?

Tell your doctor about all your medical conditions, including if:

  • You have a history of serious allergic reaction to Omvoh, any infections or liver problems.

  • You need any vaccines or have had one recently. Medicines that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during or right after treatment with Omvoh. Tell your healthcare provider that you are taking Omvoh before receiving a vaccine.

  • You are pregnant, or plan to become pregnant. It is not known if Omvoh will harm your unborn baby. There will be a pregnancy registry to collect information about women who are exposed to Omvoh during pregnancy. If you become pregnant while taking Omvoh, you are encouraged to report your pregnancy to Eli Lilly and Company at 1-800-545-5979.

  • You are breastfeeding or plan to breastfeed. It is not known if Omvoh passes into your breastmilk.

  • You take prescription or over-the-counter medicines, vitamins, or herbal supplements.

How to take

Follow your healthcare provider’s instructions for using Omvoh. You will receive your first 3 doses of Omvoh through a vein in your arm (intravenous infusion) in a healthcare facility by a healthcare provider every 4 weeks. Each infusion will last about 30 minutes (for ulcerative colitis) or about 90 minutes (for Crohn’s disease). After induction, you will continue to receive Omvoh maintenance doses as self-injections under the skin (subcutaneous injection) every 4 weeks. For these injections, Omvoh is available as prefilled pens or prefilled syringes. For a full dose you will need two injections with either two prefilled pens or two prefilled syringes. Inject 1 Omvoh prefilled pen or prefilled syringe followed right away by the other Omvoh prefilled pen or prefilled syringe. If you give injections at home, you should be trained on the correct way to prepare and inject Omvoh. Do not try to inject Omvoh yourself until you or your caregiver have been shown how to inject. Read the detailed Instructions for Use about how to use and dispose of Omvoh the correct way.

Learn more

Omvoh is a prescription medicine. During induction, Omvoh is available as a single-dose vial for intravenous infusion containing 300 mg/15 mL that is administered in a healthcare facility.

During maintenance, Omvoh is available as:

  • For ulcerative colitis: two 100 mg/mL prefilled pens or prefilled syringes.

  • For Crohn’s disease: one 100 mg/mL prefilled pen or prefilled syringe and one 200 mg/2 mL prefilled pen or prefilled syringe.

For more information, call 1-800-545-5979 or go to omvoh.lilly.com.

This summary provides basic information about Omvoh but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Omvoh and how to take it. Your doctor is the best person to help you decide if Omvoh is right for you.

MR CON BS CD APP

Omvoh® and its delivery device base are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

INDICATIONS

Omvoh® (ahm-VOH) is a medicine used to treat

  • adults with moderately to severely active ulcerative colitis

  • adults with moderately to severely active Crohn’s disease

It is not known if Omvoh is safe and effective in children under 18 years of age.